This trial is testing a new cancer drug that targets the EGFR protein. The drug is being tested to see if it is safe and effective at treating cancer.
8 Primary · 31 Secondary · Reporting Duration: Up to 42 months
Experimental Treatment
190 Total Participants · 7 Treatment Groups
Primary Treatment: BLU-945 · No Placebo Group · Phase 1 & 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Nevada | 100.0% |
65+ | 100.0% |
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute | 100.0% |
Met criteria | 100.0% |